Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Maximum Age: 80
Healthy Volunteers: f
View:
• Insulinoma verified by pathology (often from EUS-FNB-sampling)
Locations
Other Locations
Sweden
Sahlgrenska Univeristy Hospital
RECRUITING
Gothenburg
Contact Information
Primary
Per Hedenström, Associate Professor
per.hedenstrom@vgregion.se
+46 31 3421000
Backup
Riadh Sadik, Associate Professor
+46 31 3421000
Time Frame
Start Date: 2025-03-31
Estimated Completion Date: 2029-06
Participants
Target number of participants: 20
Treatments
Prospective cohort subjected to EUS-RFA
All patientens enrolled prospectively from 2025 and onwards subjected to EUS-RFA as treatemtn for pancreatic insulinoma
Control group
All patients subjected to surgery due to insulinoma during 2018-2024 acting as a historic control group
Related Therapeutic Areas
Sponsors
Leads: Sahlgrenska University Hospital